Strides Pharma Science · NSE: STAR · BSE: 532531

Q4 FY23 results · Jan–Mar 2023

Strides Pharma Science reported revenue from operations of ₹986.37 crore (up 13.9% from Q4 FY22) and net loss of ₹13.79 crore for Q4 FY23 (Jan–Mar 2023), on a consolidated basis.

Consolidated · ₹ crore
Item	Q4 FY23	Q4 FY22	YoY	Q3 FY23	QoQ
Revenue from operations	986.37	866.02	+13.9%	864.85	+14.1%
Other income	27.12	86.06	−68.5%	26.20	+3.5%
Total income	1,013.49	952.08	+6.5%	891.05	+13.7%
Profit before share of associates & JVs and tax	33.89	(58.88)	Turned profit	65.44	−48.2%
Share of profit/(loss) of associates & JVs	(40.60)	(43.64)		(143.45)
Net profit for the period	(13.79)	28.96	Turned loss	(82.11)	Loss narrowed
Attributable to shareholders of the company	(9.54)	29.22	Turned loss	(80.03)	Loss narrowed
EPS, basic (₹)	(1.06)	3.25	Turned loss	(8.86)	Loss narrowed
Net margin (%)	-1.4	3.3		-9.5

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q4 FY23	Q4 FY22	YoY	Q3 FY23	QoQ
Revenue from operations	563.56	455.66	+23.7%	386.51	+45.8%
Other income	26.38	84.83	−68.9%	29.75	−11.3%
Total income	589.93	540.49	+9.1%	416.27	+41.7%
Profit before tax	65.20	56.71	+15.0%	17.99	+262.4%
Net profit for the period	62.40	200.50	−68.9%	12.54	+397.7%
EPS, basic (₹)	6.91	22.33	−69.1%	1.39	+397.1%
Net margin (%)	11.1	44.0		3.2

Consolidated

Filed with BSE: 25 May 2023, 17:38 IST
Board meeting: 25 May 2023
Period: 01 Jan 2023 to 31 Mar 2023
Review status: Audited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 25 May 2023, 17:38 IST
Board meeting: 25 May 2023
Period: 01 Jan 2023 to 31 Mar 2023
Review status: Audited
Source: XBRL filing on BSE